BET-IN-13

Modify Date: 2025-08-25 14:51:27

BET-IN-13 Structure
BET-IN-13 structure
Common Name BET-IN-13
CAS Number 2506823-08-9 Molecular Weight 497.56
Density N/A Boiling Point N/A
Molecular Formula C28H23N3O4S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of BET-IN-13


BET-IN-13 is a potent BET inhibitor with an IC50 value of 1.6 nM. BET-IN-13 reduces LPS-induced TNF-α, IL-1β, IL-6, and NOS2 mRNA expression levels. BET-IN-13 shows anti-inflammatory activity. BET-IN-13 has the potential for the research of acute liver injury[1].

 Names

Name BET-IN-13

 BET-IN-13 Biological Activity

Description BET-IN-13 is a potent BET inhibitor with an IC50 value of 1.6 nM. BET-IN-13 reduces LPS-induced TNF-α, IL-1β, IL-6, and NOS2 mRNA expression levels. BET-IN-13 shows anti-inflammatory activity. BET-IN-13 has the potential for the research of acute liver injury[1].
Related Catalog
Target

BRD4 BD1:57.4 nM (IC50)

BRD4 BD2:44.4 nM (IC50)

BRD2 BD1:79.3 nM (IC50)

BRD2 BD2:27.5 nM (IC50)

BRD3 BD1:45.6 nM (IC50)

BRD3 BD2:18.9 nM (IC50)

BRDT BD1:87.0 nM (IC50)

BRDT BD2:43.4 nM (IC50)

In Vitro BET-IN-13 (compound 28) (1.1, 3.3, 10 µM, 2+6 h) 降低 RAW264.7 细胞中 LPS (500 ng/ml) 诱导的 TNF-α、IL-1β、IL-6 和 NOS2 mRNA 的表达水平[1]。 RT-PCR[1] Cell Line: RAW264.7 cells Concentration: 1.1, 3.3, 10 µM Incubation Time: Pre-treated for 2 h before stimulating with LPS for 6 h Result: Significantly reduced LPS (500 ng/ml) induced TNF-α, IL-1β, IL-6 and NOS2 mRNA expression levels in a dose-dependent manner.
In Vivo BET-IN-13 (3 mg/kg;静脉注射;一次) 在小鼠中显示出良好的药代动力学 (PK) 特性,T1/2 为 0.69 h,AUCINF-obs 为 609 h*ng/mL 和 Vss 为 1717 mL/kg[1]。 BET-IN-13 (37.5、75 mg/kg;腹腔注射;一次) 降低 LPS/D-GalN(d-gaiactosamine)诱导的急性肝衰竭 (ALF) 小鼠的炎症和肝损伤而无明显毒性[1]。 Animal Model: 20-22g, Female C57BL/6J mice (LPS/D-GalN(d-gaiactosamine)-induced acute liver failure (ALF))[1] Dosage: 37.5, 75 mg/kg Administration: I.p.; once Result: Reduced inflammatory responses associated with LPS/GalN-induced acute liver failure with the survival rate increased significantly to 69.2% for37.5 mg/kg and to 84.6% for 75 mg/kg.
References

[1]. Chen C, et al. Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury. Eur J Med Chem. 2022 Dec 16;247:115023.  

 Chemical & Physical Properties

Molecular Formula C28H23N3O4S
Molecular Weight 497.56
InChIKey GZEDEKFDZMUCGJ-UHFFFAOYSA-N
SMILES Cc1cc2n3c(c[nH]c(=O)c13)CN(C(=O)c1ccc3ccccc3c1)c1ccc(CS(C)(=O)=O)cc1-2
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here
Related Compounds: More...
BET-IN-1
1422554-34-4
BET-IN-2
2104688-91-5
BET-IN-12
1800343-11-6
BET-IN-9
2758778-88-8
BET-IN-7
303985-05-9
BET-IN-10
2758778-95-7
BET-IN-4
1801503-93-4
STAT3-IN-13
2248552-86-3
RET-IN-13
2684258-54-4
2-{5-amino-4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-(methylsulfanyl)-1H-pyrazol-1-yl}-N-(2-chloro-4-fluorophenyl)acetamide
1243092-84-3
2-(5-amino-4-(3-(benzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)-3-(methylthio)-1H-pyrazol-1-yl)-N-(2-chloro-4-fluorophenyl)acetamide
1242935-49-4
2-(5-amino-4-(3-(benzo[d][1,3]dioxol-5-yl)-1,2,4-oxadiazol-5-yl)-3-(methylthio)-1H-pyrazol-1-yl)-N-(2-(trifluoromethyl)phenyl)acetamide
1223781-59-6
2-{5-amino-4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-(methylsulfanyl)-1H-pyrazol-1-yl}-N-(2,5-difluorophenyl)acetamide
1242964-14-2
2-{5-amino-4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-(methylsulfanyl)-1H-pyrazol-1-yl}-N-(2-methylphenyl)acetamide
1243019-16-0
2-{5-amino-4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-(methylsulfanyl)-1H-pyrazol-1-yl}-N-(3-chloro-4-methylphenyl)acetamide
1242875-02-0
2-{5-amino-4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-(methylsulfanyl)-1H-pyrazol-1-yl}-N-(2,5-dimethoxyphenyl)acetamide
1243061-62-2
2-{5-amino-4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-(methylsulfanyl)-1H-pyrazol-1-yl}-N-phenylacetamide
1242911-34-7
2-(5-amino-4-(3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)-3-(methylthio)-1H-pyrazol-1-yl)-N-(3-chloro-4-methylphenyl)acetamide
1242957-02-3
2-{5-amino-4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-(methylsulfanyl)-1H-pyrazol-1-yl}-N-(3,4-difluorophenyl)acetamide
1243073-94-0